Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive ulinastatin for hepatic ischemia-reperfusion injury during partial hepatectomy
ChiCTR1900021546Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatic ischemia-reperfusion injury (HIRI) comparing Ulinastatin group with Placebo group (2 arms). Primary endpoints: Plasma ulinastatin concentration before hepatic inflow occlusion, Liver function and 1 more. Started Dec 2019; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
hepatic ischemia-reperfusion injury (HIRI)
Beyond the preview
Go deeper on ChiCTR1900021546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021546.